XL RUNX1 consists of an orange-labeled probe hybridizing proximal to the RUNX1 gene region at 21q22.1 and a green-labeled probe hybridizing distal to the RUNX1 gene region at 21q22.1.

Probe maps for selected products have been updated. These updates ensure a consistent presentation of all gaps larger than 10 kb including adjustments to markers, genes, and related elements. This update does not affect the device characteristics or product composition. Please refer to the list to find out which products now include updated probe maps.

Probe map details are based on UCSC Genome Browser GRCh37/hg19, with map components not to scale.

Several recurrent balanced translocations and inversions, and their variants, are recognized in the WHO category acute myeloid leukemia (AML) with recurrent genetic abnormalities. Furthermore, several cytogenetic abnormalities are considered sufficient to establish the WHO diagnosis of AML with myelodysplasia-related features if 20% or more blood or marrow blasts are present.

The RUNX1 gene, located on chromosome 21q22.1, is crucial for the establishment of definite hematopoiesis and the generation of hematopoietic stem cells in the embryo. The most common translocations involving RUNX1 are the t(8;21) RUNX1T1/RUNX1 in AML and t(12;21) ETV6/RUNX1 in acute lymphoblastic leukemia (ALL), both associated with a more favorable diagnosis. More than 40 different translocation partners have currently been identified making the RUNX1 break apart probe a valuable tool in molecular cytogenetics.

Clinical Applications

• Acute Myelogenous Leukemia (AML)
• Acute Lymphoblastic Leukemia (ALL)

XL RUNX1 was hybridized to lymphocytes. One normal interphase and metaphase are shown.

• Martinez-Ramirez et al (2001) Haematologica 86:1245-1253
• Zhang et al (2002) PNAS 99:3070-3075
• Harrison et al (2014) Leukemia 28:1015-1021